Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in the Utilization of Select Analgesics and Antiemetics
DOI: https://doi.org/10.2147/jpr.s456006
IF: 2.8319
2024-05-16
Journal of Pain Research
Abstract:Terence Fullerton, 1 Glenn Pixton 2 1 Internal Medicine and Infectious Disease, Pfizer Research and Development, Pfizer Inc., Groton, CT, USA; 2 Statistics, Pfizer Inc., Groton, CT, USA Correspondence: Terence Fullerton, Internal Medicine and Infectious Disease, Pfizer Research and Development, Pfizer Inc., 445 Eastern Point Road, Groton, CT, 06355, USA, Tel +1 860-441-6548, Email Purpose: To examine use of concomitant analgesics and antiemetics during treatment with rimegepant in adults with migraine. Patients and Methods: This was a post hoc analysis of a long-term, open-label, safety study in adults with a history of 2– 14 moderate or severe migraine attacks per month. Participants self-administered rimegepant 75 mg (1) up to once daily as needed (PRN) for 52 weeks or (2) every other day plus PRN (EOD+PRN) for 12 weeks. The PRN cohort was further divided based on baseline attack frequency, with PRN (2– 8) and PRN (9– 14) cohorts having a history of 2– 8 or 9– 14 attacks per month, respectively. Use of select analgesics and antiemetics was analyzed during a 30-day pre-treatment observation period (OP) and during rimegepant treatment. Results: Overall, 1800 rimegepant-treated participants (PRN n = 1514, EOD+PRN n = 286) were included in the analysis. Select analgesics or antiemetics were used by 80.1% of participants during the OP. Among 1441 participants using analgesics or antiemetics during the OP, the proportion who did not use any analgesics or antiemetics following initiation of rimegepant treatment increased during weeks 1– 4 (36.9%), 5– 8 (52.6%), and 9– 12 (56.5%). The mean number of days per month using analgesics or antiemetics was also significantly reduced over time in all cohorts beginning at weeks 1– 4 ( P < 0.001 vs OP). This pattern of reduced analgesic or antiemetic use was consistent for all rimegepant cohorts, but was most pronounced in the EOD+PRN cohort in which 74.8% of participants reported ≥ 50% reduction in analgesic/antiemetic days at weeks 9– 12. Reduction in use was maintained over time, with 61.3% of participants not using any analgesics or antiemetics during weeks 49– 52 of PRN treatment. Conclusion: Long-term treatment with oral rimegepant was associated with reduced analgesic and antiemetic use. Clinicaltrials.gov: NCT03266588. Keywords: rimegepant, migraine, analgesics, antiemetics, clinical trial Migraine is characterized by recurring, moderate-to-severe, pulsating, unilateral head pain. 1 Migraine may also be associated with other symptoms including photophobia, phonophobia, and nausea. 1,2 Though migraine is one of the most common causes of disability globally, it is still generally underdiagnosed and under-treated. 3,4 In response, migraine awareness campaigns have been carried out at both global and local levels to improve understanding, diagnosis, and treatment. 5,6 Non–migraine-specific therapies such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, caffeinated analgesics, and antiemetics are widely used for the acute treatment of migraine. 7,8 However, the efficacy of these non-specific migraine therapies can be inadequate for more severe migraine pain. 8 These therapies are also associated with medication-overuse headache (MOH) and a variety of other adverse events. 7 Therefore, reducing the use of non-specific migraine medications may reduce total medication exposure, risk of adverse events, and medication overuse. 3,4 Further, replacing non-specific migraine medications with migraine-specific acute treatments could improve therapeutic response and enhance overall patient satisfaction with treatment. Rimegepant 75 mg, an oral small molecule calcitonin gene-related peptide receptor antagonist, is indicated in the United States, European Union, United Kingdom, and other regions for the acute treatment of migraine (taken as needed [PRN]) with or without aura and for the preventive treatment of episodic migraine (taken every other day [EOD]) in adults. 9,10 Previous clinical trials have demonstrated that acute treatment with oral rimegepant 75 mg provides rapid (within 2 hours post-dose) and sustained (over 48 hours post-dose) relief from pain and other symptoms associated with migraine (eg, nausea, photophobia, phonophobia), and is safe and well tolerated when dosed for periods of 1 year or more. 11–14 The purpose of this exploratory post hoc analysis was to assess the relationship between rimegepant administration and the use of select analgesics and antiemetics in adults with migraine. Data were from a multicenter, open-label, long-term safety study of rimegepant for the acute treatment of migraine (NCT03266588). -Abstract Truncated-
clinical neurology